ClinicalTrials.Veeva

Menu

Does Higher OT Temperature and IV Ondansetron Reduce Incidence of PSS in Parturients? (HOTON)

D

Dr Lim Siu Min

Status and phase

Unknown
Phase 4

Conditions

Tremor
Postoperative Shivering
Chills
Vomiting, Postoperative
Temperature Change, Body
Nausea, Postoperative

Treatments

Drug: Placebo
Other: Higher OT temperature range
Drug: IV Ondansetron 4mg
Other: Lower OT temperature Range

Study type

Interventional

Funder types

Other

Identifiers

NCT04654429
202073-8861 (Other Identifier)
NMRR-20-2158-56283

Details and patient eligibility

About

This study will look at the incidence of post-spinal shivering (PSS) among the obstetrics population and will investigate whether higher operation theater (OT) temperature range or/and IV Ondansetron are able to reduce the incidence of PSS. This is a double-blind, randomized, factorial study, patients will be grouped into 4 groups - LP, HP, LO, HO (L= low-temperature range, H= high-temperature range, P= placebo, O=Ondansetron). All patients undergoing cesarean section under spinal anesthesia will be recruited, and it will be conducted in obstetrics OT.

Full description

Many studies have been conducted to look at methods to prevent and treat postspinal shivering. However, there is still no clear protocol or gold standard for post-spinal shivering management. This is due to the fact that post-spinal shivering mechanisms are complex and are broadly grouped into thermoregulatory and non-thermoregulatory. Preventive measures that have been studied are broadly classified into pharmacological methods and non-pharmacological methods. For Non-pharmacological method, active warming of the patient by various methods have been found to be effective in preventing PSS. However, there is no study that looks at ways to reduce heat loss hence maintaining normothermia and preventing PSS in patients. Therefore in this study, we will be investigating if higher OT temperature will reduce the incidence of PSS. As for pharmacological methods, many drugs have been studied for examples analgesics (tramadol), opioid receptor agonists (pethidine, fentanyl), cholinesterase inhibitors (physostigmine), N-methyl-D-aspartate receptor antagonists (ketamine, magnesium sulphate), α2-central agonists (clonidine, dexmedetomidine), antiserotonergic (ondansetron) and anti-inflammatory drugs (dexamethasone). Ondansetron is usually used to prevent chemotherapy or radiotherapy-induced nausea vomiting and Post-operative nausea and vomiting. Due to the fact that it is generally a safe drug and has added benefit as an anti-emetics especially for obstetrics population, this drug is chosen to be studied. We will also look at the efficacy of the combined effect of increased OT temperature and prophylaxis ondansetron on preventing PSS.

Enrollment

628 estimated patients

Sex

Female

Ages

18 to 50 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • All elective and emergency obstetric patients who are going for lower segment caesarean section (LSCS) under spinal anaesthesia in UMMC.
  • Patient who are given combined spinal epidural anaesthesia (CSE) without epidural local anaesthetic top-up will be included.

Exclusion criteria

  1. Patients who refused to provide study consent
  2. Caesarean section planned under general or epidural anaesthesia or potential conversion to general anaesthesia intraoperatively
  3. Royal College of Obstetrics and Gynaecology (RCOG) classification of urgency caesarean section Grade I - Immediate threat to life of woman and child. (29)
  4. Patients with psychiatric disorders who are taking selective serotonin reuptake inhibitor (SSRI) and serotonin-noradrenaline reuptake inhibitor (SNRI)
  5. Patients who has problems with any types of tremor or involuntary movements and neuromuscular disorders such as Parkinson Disease and muscular dystrophy will be excluded from the study as this will interfere with the clinical interpretation of shivering
  6. Patients with history of allergic / hypersensitive reactions towards ondansetron.
  7. Patients who received ondansetron intraoperatively as anti-emetics.
  8. Recruited patients will be excluded if OT temperature on the day of recruitment does not fulfil the OT temperature range fixed for the study

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Factorial Assignment

Masking

Quadruple Blind

628 participants in 4 patient groups, including a placebo group

Lower OT temperature with placebo (LP)
Placebo Comparator group
Description:
Lower OT temperature with placebo This group function as a main control arm. Incidence of PSS will be documented usual / standard OT temperature which is 17-19 degree celsius, and without giving any pharmacological intervention to prevent PSS.
Treatment:
Other: Lower OT temperature Range
Drug: Placebo
Higher OT temperature with placebo (HP)
Active Comparator group
Description:
Higher OT temperature with placebo This group will receive one non-pharmacological intervention, which is higher OT temperature 19-22 degree celsius. The aim of this intervention is to reduce heat loss therefore incidence of PSS for obstetric population coming for lower segment cesarean section (LSCS) by reducing the temperature gradient between the body and environment.
Treatment:
Other: Higher OT temperature range
Drug: Placebo
Lower OT temperature with IV Ondansetron 4mg (LO)
Active Comparator group
Description:
Lower OT temperature with Ondansetron 4mg intravenous. This group also will receive one pharmacological intervention, which is IV ondansetron 4mg to prevent incidence of PSS under standard OT temperature 17-19 degrees.
Treatment:
Other: Lower OT temperature Range
Drug: IV Ondansetron 4mg
higher OT temperature 19-22 and IV ondansetron 4mg (HO)
Active Comparator group
Description:
This group will receive 2 interventions - higher OT temperature 19-22 and IV ondansetron 4mg. This group is designed to see if when both intervention combined, will further reduce the incidence of PSS among obstetrics population.
Treatment:
Drug: IV Ondansetron 4mg
Other: Higher OT temperature range

Trial contacts and locations

1

Loading...

Central trial contact

SIU MIN LIM, L; Tsyr Xiang Teoh, M

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems